Market Challenges And Opportunities

Global Diabetic Gastroparesis Treatment Market – Driver

Increasing Prevalence of Diabetes Worldwide

Increasing geriatric population across world

The increasing geriatric population across the world is expected to drive growth of global diabetic gastroparesis market. The diabetes is commonly seen disorder in old aged people. For instance, according to data published on World Population Prospects 2022 by United Nations Department of Economics and Social Affairs, the share of the global population aged 65 years or above is projected to rise from 10 per cent in 2022 to 16 percent in 2050. Also, globally, women outnumber men at older ages. In 2022, women comprised 55.7 per cent of persons aged 65 or older.

Global Diabetic Gastroparesis Treatment Market Segmentation:

The Global Diabetic Gastroparesis Treatment Market report is segmented into by Product Type, by Disease Indication, by Distribution channel, and Region.

By Product Type, the market is segmented into Drugs and Surgical treatments. Out of which, the drug segment is expected to hold a dominant position in the Global Diabetic Gastroparesis Treatment market during the forecast period and this is attributed to increasing number of antiemetic medication as OTC products.

By Disease Indication, the market is segmented into Compensated Gastroparesis, Gastric Failure. Out of which, the Compensated Gastroparesis segment is expected to hold a dominant position in the Diabetic Gastroparesis Treatment market during the forecast period and this is attributed to the increasing awareness and healthcare facilities, that very less number of cases are advanced to Gastric failure condition.

By Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Out of which, the Hospital Pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increasing number of hospital pharmacies.

Among all the segmentations, the product type segment has the highest potential due to the increasing research and development activities across world over the forecast period. For instance, in December 2022, Evoke Pharma, Inc., a U.S. based pharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) issued a U.S. patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis’’ which covers the usage of Gimoti (metoclopramide). Gimoti is a nasal spray used to treat diabetic gastroparesis, a complication of diabetes where the stomach's digestion slows down. Canadian Intellectual Property Office granted the company a key patent for its previously submitted application (CA 2984736). The received patent is for Gimoti’s method of use.

Global Diabetic Gastroparesis Treatment Market : Key Trends

Research and development activities across the world can drive the growth of Diabetic Gastroparesis Treatment market within the forecast period. For instance, according to article published in Journal Europe PMC on July 29, 2022, Chinese herbal medicine Zhi Shi Xiao Pi Wan has an effect on adult diabetic gastroparesis with lesser side effects.

In December 14, 2022, a clinical trial by Mayo clinic, a U.S. based academic medical center was initiated on use of Rifaximin for treatment of diabetic gastroparesis.

Global Diabetic Gastroparesis Treatment Market : Restraint

Termination of clinical trials

Withdrawal/termination of clinical trials is also expected to hamper growth of the market. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is due to early termination of clinical trials or failure of drugs to meet statistically significant endpoints. For instance, in October 23, 2020, clinical trials on use of Docusate/ Senna for treatment of Diabetic Gastroparesis was terminated due to lack of recruitment.

Lack of awareness about the disease

Diabetic gastroparesis is a significant gastrointestinal condition. However, a substantial population is unaware or have very less information regarding the symptoms, possible treatments of the disease. According to study published in Journal of Neurogastroenterology and Motility on October 17, 2020, a survey was conducted with total 490 doctors across Asia. It was found that only 41.7% respondents had access to gastric emptying scintigraphy. Most of doctors had never diagnosed gastroparesis at all or diagnosed fewer than 5 patients a year due to lack of awareness amongst people.

Key Opportunities in the Market: